Covariation of human microsomal protein per gram of liver with age: Absence of influence of operator and sample storage may justify interlaboratory data pooling

Drug Metabolism and Disposition

Volumn 36, Issue 12, 2008, Pages 2405-2409

  Barter, Zoe E ^a,b,e   Chowdry, J E ^a   Harlow, J R ^a   Snawder, J E ^c   Lipscomb, J C ^d   Rostami Hodjegan, A ^a,b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b CERTARA UK LIMITED   (United Kingdom)

^c NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH   (United States)

^d U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^e ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; CYTOCHROME P450; MICROSOME PROTEIN; UNCLASSIFIED DRUG;

AGE; ARTICLE; CONTROLLED STUDY; FROZEN SECTION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; INDIVIDUALIZATION; LIVER CLEARANCE; LIVER HOMOGENATE; LIVER MICROSOME; METABOLIC CLEARANCE RATE; OPERATOR; PRIORITY JOURNAL; STORAGE;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; CLINICAL CHEMISTRY TESTS; CRYOPRESERVATION; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; FETUS; HUMANS; LINEAR MODELS; MALE; MICROSOMES, LIVER; MIDDLE AGED; MODELS, STATISTICAL; OBSERVER VARIATION; PROTEINS; SPECIMEN HANDLING; YOUNG ADULT;

EID: 57349120552     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.021311     Document Type: Article

References (21)

1. Andersson TB, Bredberg E, Ericsson H, and Sjöberg H (2004) An evaluation of the in vitro metabolism data for predicting the clearance and drug-drug interaction potential of CYP2C9 substrates. Drug Metab Dispos 32:715-721.
2. Bäärnhielm C, Dahlbäck H, and Skånberg I (1986) In vivo pharmacokinetics of felodipine predicted from in vitro studies in rat, dog and man. Acta Pharmacol Toxicol (Copenh) 2:113-122.
3. Barter ZE, Bayliss MK, Beaune PH, Boobis AR, Carlile DJ, Edwards RJ, Houston JB, Lake BG, Lipscomb JC, Pelkonen OR, et al. (2007) Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Curr Drug Metab 8:33-45.
4. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
5. Chiba M, Fujita S, and Suzuki T (1990) Pharmacokinetic correlation between in vitro hepatic microsomal enzyme kinetics and in vivo metabolism of imipramine and desipramine in rats. J Pharm Sci 79:281-287.
6. Gabrielsson J and Weiner D (2007) Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications, 3rd ed, Swedish Pharmaceutic Press, Stockholm.
7. Houston JB (1994) Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 47:1469-1479.
8. Joly JG, Doyon C, and Peasant Y (1975) Cytochrome P-450 measurement in rat liver homogenate and microsomes: its use for correction of microsomal losses incurred by differential centrifugation. Drug Metab Dispos 3:577-586.
9. Lin JH, Hayashi M, Awazu S, and Hanano M (1978) Correlation between in vitro and in vivo drug metabolism rate: oxidation of ethoxybenzamide in rat. J Pharmacokinet Biopharm 6:327-337.
10. Lipscomb JC and Garrett CM (1998) Effect of organ procurement conditions on cytochrome P-450 activity in rat liver microsomes. In Vitro Mol Toxicol 11:265-270.
11. Matsubara T, Koike M, Touchi A, Tochino Y, and Sugeno K (1976) Quantitative determination of cytochrome P-450 in rat liver homogenate. Anal Biochem 75:596-603.
12. Obach RS (1997) Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol. Drug Metab Dispos 25:1359-1369.
13. Pearce RE, McIntyre CJ, Madan A, Sanzgiri U, Draper AJ, Bullock PL, Cook DC, Burton LA, Latham J, Nevins C, et al. (1996) Effects of freezing, thawing, and storing human liver microsomes on cytochrome P450 activity. Arch Biochem Biophys 331:145-169.
14. Pelkonen O, Kaltiala EH, Larmi TK, and Kärki NT (1973) Comparison of activities of drug-metabolizing enzymes in human fetal and adult livers. Clin Pharmacol Ther 14:840-846.
15. Powis G, Jardine I, Van Dyke R, Weinshilboum R, Moore D, Wilke T, Rhodes W, Nelson R, Benson L, and Szumlanski C (1988) Foreign compound metabolism studies with human liver obtained as surgical waste: relation to donor characteristics and effects of tissue storage. Drug Metab Dispos 16:582-589.
16. Rostami-Hodjegan A and Tucker GT (2007) Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discov 6:140-148.
17. Soars MG, Burchell B, and Riley RJ (2002) In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance. J Pharmacol Exp Ther 301:382-390.
18. Uchaipichat V, Winner LK, Mackenzie PI, Elliot DJ, Williams JA, and Miners JO (2006) Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation. Br J Clin Pharmacol 61:427-439.
19. von Bahr C, Groth CG, Jansson H, Lundgren G, Lind M, and Glaumann H (1980) Drug metabolism in human liver in vitro: establishment of a human liver bank. Clin Pharmacol Ther 27:711-725.
20. Wilson ZE, Rostami-Hodjegan A, Burn JL, Tooley A, Boyle J, Ellis SW, and Tucker GT (2003) Inter-individual variability in levels of human microsomal protein and hepatocellularity per gram of liver. Br J Clin Pharmacol 56:433-440.
21. Yamazaki H, Inoue K, Turvy CG, Guengerich FP, and Shimada T (1997) Effects of freezing, thawing, and storage of human liver samples on the microsomal contents and activities of cytochrome P450 enzymes. Drug Metab Dispos 25:168-174.